Close Menu

NEW YORK (GenomeWeb) – Myriad Genetics will be ION Solutions' preferred partner for providing hereditary cancer genetic testing to its member practices, the firms announced today.

ION Solutions is an organization under AmerisourceBergen that provides expertise, technologies, and resources to more than half the community-based oncology practices in the US. Myriad markets MyRisk Hereditary Cancer, a 28-gene panel that assesses whether patients have an increased risk for eight cancers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.